Youngs Advisory Group Inc. grew its holdings in OraSure Technologies, Inc. (NASDAQ:OSUR) by 19.4% during the second quarter, Holdings Channel reports. The fund owned 33,972 shares of the medical instruments supplier’s stock after purchasing an additional 5,508 shares during the period. OraSure Technologies accounts for about 0.4% of Youngs Advisory Group Inc.’s investment portfolio, making the stock its 23rd biggest holding. Youngs Advisory Group Inc.’s holdings in OraSure Technologies were worth $560,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in OraSure Technologies during the 1st quarter worth approximately $113,000. Cubist Systematic Strategies LLC purchased a new position in OraSure Technologies during the 1st quarter worth approximately $139,000. Private Advisor Group LLC purchased a new position in OraSure Technologies during the 1st quarter worth approximately $181,000. Engineers Gate Manager LP purchased a new position in OraSure Technologies during the 2nd quarter worth approximately $197,000. Finally, Xact Kapitalforvaltning AB purchased a new position in OraSure Technologies during the 2nd quarter worth approximately $198,000. Institutional investors and hedge funds own 95.08% of the company’s stock.
OSUR opened at $16.16 on Wednesday. The company has a market capitalization of $1.03 billion, a PE ratio of 31.69, a price-to-earnings-growth ratio of 4.26 and a beta of 1.56. OraSure Technologies, Inc. has a 12 month low of $12.86 and a 12 month high of $23.01.
A number of research analysts recently issued reports on OSUR shares. TheStreet upgraded OraSure Technologies from a “c+” rating to a “b” rating in a research note on Thursday, August 9th. ValuEngine upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Friday, July 6th. Stephens downgraded OraSure Technologies from an “overweight” rating to an “equal weight” rating in a research note on Monday, July 16th. Finally, Zacks Investment Research raised OraSure Technologies from a “sell” rating to a “hold” rating and set a $17.00 price objective for the company in a research report on Wednesday, May 2nd. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $21.33.
OraSure Technologies Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Featured Article: Google Finance Portfolio
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.